Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia

International Journal of Hematology

Volumn 99, Issue 1, 2014, Pages 41-52

  Kumagai, Takashi ^a   Matsuki, Eri ^b   Inokuchi, Koiti ^c   Ohashi, Kazuteru ^d   Shinagawa, Atsushi ^e   Takeuchi, Jin ^f   Yoshida, Chikashi ^g   Okamoto, Shinichiro ^b   Wakita, Hisashi ^h   Kozai, Yasuji ⁱ   Shirasugi, Yukari ^j   Fujisawa, Shin ^k   Iwase, Osamu ^l   Yano, Shingo ^m   Nishiwaki, Kaichi ⁿ   Oba, Koji ^o   Sakamoto, Junichi ^p   Sakamaki, Hisashi ^d  

^a Ohme Municipal General Hospital   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

^d TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^e Hitachi   (Japan)

^f NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g NATIONAL HOSPITAL ORGANIZATION MITO MEDICAL CENTER   (Japan)

^h NARITA RED CROSS HOSPITAL   (Japan)

ⁱ TOKYO METROPOLITAN TAMA MEDICAL CENTER   (Japan)

^j TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^l TOKYO MEDICAL UNIVERSITY   (Japan)

^m JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁿ JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^o HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^p Tokai Central Hospital of Japan Mutual Aid Association of Public School Teachers   (Japan)

more..

Author keywords

CML; Dasatinib; Lymphocytosis

Indexed keywords

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; FUSION PROTEINS, BCR-ABL; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, CHRONIC-PHASE; LYMPHOCYTE COUNT; LYMPHOCYTE SUBSETS; MALE; MIDDLE AGED; NEOPLASM STAGING; PHENOTYPE; PROGNOSIS; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84899098640     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-013-1483-9     Document Type: Article

References (41)

1. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341:164-72. (Pubitemid 29325745)
2. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247:1079-82.
3. Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 2002;8:935-42. (Pubitemid 34520420)
4. Gleevec (imatinib mesylate) tablets: prescribing information, Rev. edn. East Hanover: Novartis Pharmaceuticals, November 2007.
5. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood. 2008;112:4808-17.
6. The chronic myelogenous leukemia clinical practice guidelines in oncology, version 1. Washington, DC: National Comprehensive Cancer Network, 2009.
7. Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European leukemia net. Blood. 2006;108:1809-20. (Pubitemid 44394987)
8. Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European leukemia net. J Clin Oncol. 2009;27:6041-51.
9. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260-70.
10. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, ENESTnd Investigators, et al. Nilotinib versus imatinib for-newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010;362:2251-9.
11. Sprycel (dasatinib): prescribing information, Rev. edn. New York: Bristol-Myers Squibb, November 2007.
12. Mannaioni PF, Di Bello MG, Masini E. Platelets and inflammation: role of platelet-derived growth factor, adhesion molecules and histamine. Inflamm Res. 1997;46:4-18. (Pubitemid 27068295)
13. Appel S, Balabanov S, Brümmendorf TH, Brossart P. Effects of imatinib on normal hematopoiesis and immune activation. Stem Cells. 2005;23:1082-8. (Pubitemid 41377724)
14. Chen J, Schmitt A, Chen B, Rojewski M, Rübeler V, Fei F, et al. Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling. J Cell Mol Med. 2008;12(5B):2107-18.
15. Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, Zhang R, et al. Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation. Blood. 2008;111:1366-77. (Pubitemid 351213423)
16. Blake SJ, Bruce Lyons A, Fraser CK, Hayball JD, Hughes TP. Dasatinib suppresses in vitro natural killer cell cytotoxicity. Blood. 2008;111:4415-6.
17. Schade AE, Schieven GL, Townsend R, Jankowska AM, Susulic V, Zhang R, et al. Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo. Exp Hematol. 2009;37:256-65.
18. Porkka K, Khoury HJ, Paquette RL, Matloub Y, Sinha R, Cortes JE. Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer. 2010;116:377-86.
19. Kreutzman A, Juvonen V, Kairisto V, Ekblom M, Stenke L, Seggewiss R, et al. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood. 2010;116:772-82.
20. Nagata Y, Ohashi K, Fukuda S, Kamata N, Akiyama H, Sakamaki H. Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion. Int J Hematol. 2010;91:799-807.
21. Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia. 2009;23:1398-405.
22. Kim DH, Kamel-Reid S, Chang H, Sutherland R, Jung CW, Kim HJ, et al. Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia. Haematologica. 2009;94:135-9.
23. Valent JN, Schiffer CA. Prevalence of large granular lymphocytosis in patients with chronic myelogenous leukemia (CML) treated with dasatinib. Leuk Res. 2011;35:e1-3.
24. Lee SJ, Jung CW, Kim DY, Lee KH, Sohn SK, Kwak JY, Kim HJ, Kim IH, Park S, Kim DH. Retrospective multicenter study on the development of peripheral lymphocytosis following secondline dasatinib therapy for chronic myeloid leukemia. Am J Hematol. 2011;86:346-50.
25. Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, et al. Association of lymphocytosis following treatment with dasatinib with response and outcome (abstract). J Clin Oncol. 2010;28(15s):Abstract 6553.
26. Jabbour E, Hochhaus A, Cortes J, La Rosée P, Kantarjian HM. Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. Leukemia. 2010;24:6-12.
27. Yoshida C, Fletcher L, Ohashi K, Wakita H, Kumagai T, Shiseki M, et al. Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan. Int J Clin Oncol. 2012;17(6):584-9.
28. Sokol L, Loughran TP Jr. Large granular lymphocyte leukemia. Oncologist. 2006;11:263-73.
29. A Hochhaus, G Saglio, C Chuah, C Pavlovsky, MB Bradley-Garelik, A Lambert et al. Dasatinib and imatinib-induced reductions in BCR-ABL transcript levels ≤10% at 3 months are associated with improved responses in patients with newly diagnosed CML-CP: analysis of molecular response kinetics in the DASISION Trial (abstract). Ann Meet Am Soc Hematol. 2011;Abstract 2767.
30. Hanfstein B, Müller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012;26:2096-102.
31. Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012;30:232-8.
32. Veldurthy A, Patz M, Hagist S, Pallasch CP, Wendtner CM, Hallek M, et al. The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes. Blood. 2008;112:1443-52.
33. Mahon FX, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11:1029-35.
34. Takahashi N, Kyo T, Maeda Y, Sugihara T, Usuki K, Kawaguchi T, et al. Discontinuation of imatinib in Japanese patients with chronic myeloid leukemia. Haematologica. 2012;97:903-6.
35. Tanaka H, Nakashima S, Usuda M. Rapid and sustained increase of large granular lymphocytes and rare cytomegalovirus reactivation during dasatinib treatment in chronic myelogenous leukemia patients. Int J Hematol. 2012;96:308-19.
36. Mustjoki S, Auvinen K, Kreutzman A, Rousselot P, Hernesniemi S, Melo T, et al. Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy. Leukemia. 2013;27:914-24.
37. Bristol-Myers Squibb. Pharmacokinetics, study CA180-031. (http://www.bms.co.jp/medical/sprycel/11.html). November, 2012.
38. Kreutzman A, Ladell K, Koechel C, Gostick E, Ekblom M, Stenke L, et al. Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation. Leukemia. 2011;25:1587-97.
39. Powers JJ, Dubovsky JA, Epling-Burnette PK, Moscinski L, Zhang L, Mustjoki S, et al. A molecular and functional analysis of large granular lymphocyte expansions in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors. Leuk Lymphoma. 2011;52:668-79.
40. Cervantes F, Pierson BA, McGlave PB, Verfaillie CM, Miller JS. Autologous activated natural killer cells suppress primitive chronic myelogenous leukemia progenitors in long-term culture. Blood. 1996;87:2476-85. (Pubitemid 26086893)
41. Silla LM, Pincus SM, Locker JD, Glover J, Elder EM, Donnenberg AD, et al. Generation of activated natural killer (A-NK) cells in patients with chronic myelogenous leukaemia and their role in the in vitro disappearance of BCR/abl-positive targets. Br J Haematol. 1996;93:375-85. (Pubitemid 26148741)